Abstracts Archive - Page 1594 of 2425 - ACR Meeting Abstracts

Abstract Number: 2655 • 2016 ACR/ARHP Annual Meeting
Prevalence and Risk Factors of Reactivation of Resolved Hepatitis B Virus in Rheumatoid Arthritis Patients Treated with Biological Disease-Modifying Anti-Rheumatic Drugs
Toshiyuki Watanabe¹, Shinji Fukaya² and Kazumasa Akikawa², ¹3rd Department of Internal Medicine, Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Obihiro, Japan, ²3rd Department of Internal medicine, Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Obihiro, Japan
Background/Purpose: Reactivation of hepatitis B virus (HBV) is one of the most serious complications in rheumatoid arthritis (RA) patients treated with biological disease-modifying anti-rheumatic drugs…
Abstract Number: 2656 • 2016 ACR/ARHP Annual Meeting
Resume of Biologic Therapy after Tuberculosis Infection in Patients with Inflammatory Arthropathies. Daily Clinical Practice Data from an Endemic Country
Liliana Uribe Botero¹, Margarita A Saldarriaga Alvarez¹, Natalia Duque Zapata¹, Johnny Urrego¹, Oscar Jair Felipe Diaz¹, Carmen Cerón², Alejandro Uribe¹, Luis Alonso Gonzalez^1,3 and José A. Gómez-Puerta¹, ¹Medicarte IPS, Medellín, Colombia, Medellín, Colombia, ²Medicarte IPS, Medellín, Colombia, ³Rheumatology Unit, Universidad de Antioquia, Medellin, Colombia
Background/Purpose: Long-term extension studies and observational drug registers mainly from Western countries or non-endemic areas have reported an increased risk of tuberculosis (TB) infection in…
Abstract Number: 2657 • 2016 ACR/ARHP Annual Meeting
Withdrawal of Nonsteroidal Anti-Inflammatory Drugs in Rheumatoid Arthritis Patients with Low Disease Activity
Dong Jin Go^1,2, Kichul Shin³, Han Joo Baek⁴, Seong-Wook Kang⁵, Young Mo Kang⁶, Jae-Bum Jun⁷, Yun Jong Lee⁸, Sung-Hwan Park⁹ and Yeong Wook Song^10,11, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, The Republic of, ²Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea, ⁵Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, South Korea, ⁷Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, The Republic of, ⁸Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea, ¹⁰Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ¹¹Department of Molecular Medicine and Biopharmaceutical Sciences, BK21 plus Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul National University, Seoul, South Korea
Background/Purpose: Although nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in relieving joint pain in rheumatoid arthritis (RA) patients, long-term use of NSAIDs can cause adverse effects.…
Abstract Number: 2658 • 2016 ACR/ARHP Annual Meeting
Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Rheumatoid Arthritis
Zulema Rosales Rosado^1,2, Judit Font Urgelles¹, Dalifer Freites Núñez¹, Cynthia Milagros León Cárdenas¹, Cristina Lajas Petisco¹, Leticia Leon², Luis Rodriguez Rodriguez², Juan A Jover Jover¹ and Lydia Abásolo Alcázar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: There is a high risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. After more…
Abstract Number: 2659 • 2016 ACR/ARHP Annual Meeting
Respiratory Symptoms in Patients with Primary SjöGren’s Syndrome – a Case-Control Study
Thomas Mandl¹, Peter Olsson¹, Roger Hesselstrand² and Victor Strevens Bolmgren³, ¹Dept of Rheumatology, Skane University Hospital Malmö, Lund University, Malmo, Sweden, ²Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ³Dept of Rheumatology, Skane University Hospital Malmo, Lund University, Malmo, Sweden
Background/Purpose: To evaluate the amount and impact of respiratory symptoms in patients with primary Sjögren’s syndrome (pSS) and to assess if such symptoms are related…
Abstract Number: 2660 • 2016 ACR/ARHP Annual Meeting
Do Ultrasonographic Lesions of Salivary Glands Evolve in SjöGren Patients during Follow-up ?
Alain Saraux¹, Valerie Devauchelle², Sandrine Jousse-Joulin³, Divi Cornec⁴, Pierre Gazeau⁵ and Dewi Guellec⁵, ¹Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ²Service de Rhumatologie, Department of Rheumatology, Brest University Hospital, Brest, France, Brest, France, ³Rheumatology, CHu La cavle Blanche, Brest, France, ⁴Department of rheumatology, Brest Occidentale University, Brest, France, ⁵Rheumatology, CHU Brest, Brest, France
Background/Purpose: to evaluate if the salivary glands ultrasonographic score (SGUS) is modified during follow-up in primitive Sjögren patients (pSS) and to compare pSS with idiopathic…
Abstract Number: 2661 • 2016 ACR/ARHP Annual Meeting
Performance of the Proposed ACR-EULAR Criteria for Sjogren’s Syndrome in a Prospective Multidisciplinary Diagnostic Cohort from Daily Clinical Practice
Jolien F. van Nimwegen¹, Martha S. van Ginkel¹, Suzanne Arends¹, Gwenny M. Verstappen¹, Erlin A. Haacke^1,2, Bert van der Vegt³, Nicole Sillevis Smitt-Kamminga⁴, Fred K.L. Spijkervet⁵, Frans G.M. Kroese¹, Arjan Vissink⁶ and Hendrika Bootsma¹, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Pathology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁴Opthalmology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁵Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁶Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Sjögren’s syndrome (SS) is a systemic auto-immune disease with a heterogeneous clinical presentation. Recently, ACR-EULAR criteria were proposed for classification of SS, which combine…
Abstract Number: 2662 • 2016 ACR/ARHP Annual Meeting
Effect of Tobacco Smoking on the Clinical, Histopathological, and Serological Manifestations of SjöGren’s Syndrome
Astrid Rasmussen¹, Donald U. Stone², Dustin Fife³, Michael Brown⁴, Keith Earley⁵, Lida Radfar⁶, C. Erick Kaufman⁷, David M. Lewis⁸, Nelson L. Rhodus⁹, Barbara M. Segal¹⁰, Daniel J Wallace¹¹, Michael Weisman¹², Swamy Venuturupalli¹³, Michael T. Brennan¹⁴, Christopher J Lessard³, Courtney G. Montgomery¹⁵, R. Hal Scofield¹⁵ and Kathy L. Sivils¹⁵, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA, Oklahoma City, OK, ²King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Pfizer Inc., Groton, CT, ⁵59th Medical Wing, US Air Force, San Antonio, TX, ⁶Oral Diagnosis and Radiology Department, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁷Medicine, University of Oklahoam Health Sciences Center, Oklahoma City, OK, ⁸Department of Oral and Maxillofacial Pathology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁹Department of Diagnostic and Biological Sciences, University of Minnesota School of Dentistry, Minneapolis, MN, ¹⁰Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN, ¹¹Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹²Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹³Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA, ¹⁴Department of Oral Medicine, Carolinas Medical Center, Charlotte, NC, ¹⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: To assess the prevalence of smoking in patients with Sjögren’s syndrome (SS) and non-Sjögren’s sicca (non-SS sicca), and the association of smoking habits with…
Abstract Number: 2663 • 2016 ACR/ARHP Annual Meeting
Antimalarials Protect Against Damage Accrual in Primary SjöGren’s Syndrome
Gabriela Hernandez-Molina¹, Valeria Valim², Yemil Atisha-Fregoso³, Anastasia Secco⁴, Emmanuel Guerra⁵, Marianela Adrover⁵, Anna Julha Lage Santos⁶ and Antonio Catalan Pellet⁴, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico City, Mexico, ²Rheumatology, Department of Medicine, Universidade Federal do Espírito Santo, Vitória, Brazil, Vitória, Brazil, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁴Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ⁵Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ⁶Universidade Federal do Espírito Santo, Vitória, Brazil
Background/Purpose: Antimalarials are frequently used in patients with primary Sjögren’s syndrome (SS). The aim of this study was to assess their impact on damage accrual…
Abstract Number: 2664 • 2016 ACR/ARHP Annual Meeting
Evaluation of Thyroid Autoimmune Disease in Primary SjöGren’s Syndrome and Its Association with Disease Phenotype
Mario Giron-Pillado¹, Yemil Atisha-Fregoso¹, Ivette Cruz-Bautista¹, Miguel Astudillo-Angel¹ and Gabriela Hernandez-Molina², ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico City, Mexico
Background/Purpose:
Abstract Number: 2665 • 2016 ACR/ARHP Annual Meeting
Epratuzumab Treatment of Patients with Systemic Lupus Erythematosus and Secondary Sjogren’s Syndrome: An Exploratory Analysis of Phase 3 Studies
Jacques-Eric Gottenberg¹, Thomas Dörner², Hendrika Bootsma³, Valerie Devauchelle-Pensec⁴, Simon Bowman⁵, Gordana Kosutic⁶, Holger Bartz⁷, Marga Oortgiesen⁶, Anthony Shock⁸, Willem Koetse⁶, Catrinel Galateanu⁹, Sabine Bongardt⁷, Xavier Mariette¹⁰ and Caroline Gordon^11,12, ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Department of Medicine/Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, University of Groningen, Groningen, Netherlands, ⁴Department of Rheumatology and Unit of Immunology, Brest University Medical School, Brest, France, ⁵Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ⁶UCB Pharma, Raleigh, NC, ⁷UCB Pharma, Monheim, Germany, ⁸UCB Pharma, Slough, United Kingdom, ⁹UCB Pharma, Brussels, Belgium, ¹⁰INSERM U1184, Université Paris-Sud, Paris, France, Le Kremlin Bicetre, France, ¹¹NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ¹²Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: The EMBODY 1 (SL0009; NCT01262365) and EMBODY 2 (SL0010; NCT01261793) phase 3 studies investigated the efficacy and safety of epratuzumab (Emab; Immunomedics Inc), a…
Abstract Number: 2666 • 2016 ACR/ARHP Annual Meeting
Therapeutic Efficacy of Iguratimod in Patients with Primary Sjogren’s Syndrome
Lingshu Zhang¹, Wei Jiang², Cong-Qiu Chu³, Yi Liu⁴ and Yi Liu, ¹Department of Rheumatology, West China Hospital, Sichuan University, Chengdu, China, ²The Ninth People's Hospital of Chongqing, Chongqing, China, ³Rheumatology, Oregon Health & Science University, Portland, OR, ⁴Department of Rheumatology and Immunology, West China Hospital of Sichuan University, Chengdu, China
Background/Purpose: Iguratimod (IGU), a methanesulfonanilide, has been used as a novel disease-modifying antirheumatic drug for treatment of rheumatoid arthritis in Japan and China. IGU displayed significantly inhibition…
Abstract Number: 2667 • 2016 ACR/ARHP Annual Meeting
Whole Frequency Audiometrical Correlation with Disease Activity in Primary SjöGren’s Syndrome in Hispanic Population
Janett Riega-Torres¹, Yolisa Hinojosa-Rios², Jose Luis Treviño-González², Lorena Pérez-Barbosa³, Mario Alberto Garza-Elizondo⁴, David Vega-Morales⁵, Amaury Valdés-Mancha⁶, Jorge Esquivel-Valerio⁴, Mario Jesus Villegas-Gonzalez², Cassandra Skinner-Taylor³ and Diana Flores-Alvarado⁷, ¹Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Servicio de Otorrinolaringología y Cirugía de Cabeza y Cuello. Hospital Universitario “Dr. José Eleuterio González”. Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Hospital Universitario, Monterrey, Mexico, ⁴Rheumatology, Hospital Universitario, UANL., Monterrey, Mexico, ⁵Universidad Autónoma de Nuevo Léon, Monterrey, Mexico, ⁶Servicio de Reumatología, Departamento de Medicina Interna. Hospital Universitario “Dr. José Eleuterio González”. Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁷Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”. Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Sjögren's syndrome is an autoimmune disorder that can develop hearing loss, It can be diagnosed with high frequency audiometry. Our study aims to correlate…
Abstract Number: 2668 • 2016 ACR/ARHP Annual Meeting
Real Time Sonoelastography in Primary Sjögren’s Syndrome Correlates with Morphological Ultrasonographic Features and Glandular Activity but Not with Glandular Fibrosis
Gabriela Hernandez-Molina¹, Luis Azpeitia², Sergio Criales-Vera³, Carlos Pacheco⁴, Edgardo Reyes⁵, Guadualupe Lima⁴, Luis Llorente⁶ and Eric Kimura-Hayama³, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico City, Mexico, ²Radiology, Instituto Nacional de Cardiologia, Mexico City, Mexico, ³Radiology Department, Instituto Nacional de Cardiologia, Mexico City, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁵Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁶Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Salivary gland ultrasonography is a highly specific tool for the diagnosis of primary Sjögren´s syndrome (PSS). Real time sonoelastography (RTS) is a novel imaging…
Abstract Number: 2669 • 2016 ACR/ARHP Annual Meeting
Biological Treatments in Primary SjöGren Syndrome
Monica Fernandez Castro¹, Jose Luis Andreu², Carlos Sánchez-Piedra³, Víctor Martínez Taboada⁴, Alejandro Olivé⁵, José Rosas⁶, Raúl Menor Almagro⁷, Beatriz Rodriguez Lozano⁸, Angel Garcia-Aparicio⁹, Francisco Javier López Longo¹⁰, Sara Manrique-Arija¹¹, Jesus Alberto Garcia Vadillo¹², Susana Gil Barato¹³, Ruth Lopez Gonzalez¹⁴, Javier Narváez¹⁵, Carlos Galisteo¹⁶ and on behalf of Sjogren-SER project (GEEAS-SER), ¹Rheumatology, Hospital Infanta Sofía, Madrid, Spain, ²Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ³Unidad de Investigación de la Sociedad Española de Reumatología, Madrid, Spain, ⁴Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ⁵Rheumatology, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ⁶Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ⁷Rheumatology, Hospital General de Jerez de la Frontera, Jerez de la Frontera, Spain, ⁸Rheumatology, Hospital de Canarias, S/C Tenerife, Spain, ⁹Rheumatology, Hospital Virgen de la Salud, Toledo, Spain, ¹⁰Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, ¹¹Rheumatology, Hospital Carlos Haya, Malaga, Spain, ¹²Rheumatology, Hospital La Princesa, Madrid, Spain, ¹³Rheumatology, Hospital General de Alicante, Alicante, Spain, ¹⁴Rheumatology, Hospital Virgen de la Concha, Salamanca, Spain, ¹⁵Rheumatology Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain, ¹⁶Rheumatology, Hospital Parc-Taulí, Sabadell, Spain
Background/Purpose: Primary Sjögren syndrome (pSS) is a systemic autoimmune disease involving mainly the exocrine glandular system. Nevertheless, its clinical spectrum includes the development of multiple…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].